{"filing":{"accession_number":"0001171843-26-006704","cik":"0001898416","ticker":"ALVOW","company_name":"Alvotech","form":"6-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"f6k_102026.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1898416/000117184326006704/f6k_102026.htm"},"events":[{"id":36278,"run_id":33444,"accession_number":"0001171843-26-006704","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces FDA approval of a new manufacturing process for SIMLANDI® (adalimumab-ryvk) that more than doubles drug substance output per batch. While the disclosure involves regulatory approval, the core event is an operational/manufacturing milestone—process optimization and capacity expansion—rather than a discrete regulatory filing or approval of a new product. The announcement emphasizes manufacturing productivity gains and operational flexibility, making it an operational achievement rather than a financial, governance, or legal event. This is material to investors as it affects the company's ability to meet growing demand and optimize existing infrastructure.","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40639,"accession_number":"0001171843-26-006704","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of a new manufacturing process for SIMLANDI® (adalimumab-ryvk) that more than doubles drug substance output per batch. While the disclosure involves regulatory approval, the core event is an operational/manufacturing milestone—process optimization and capacity expansion—rather than a discrete regulatory filing or approval of a new product. The announcement emphasizes manufacturing productivity gains and operational flexibility, making it an operational achievement rather than a financial, governance, or legal event. This is material to investors as it affects the company's ability to meet growing demand and optimize existing infrastructure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:00:42.754049+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40639,"accession_number":"0001171843-26-006704","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces FDA approval of a new manufacturing process for SIMLANDI® (adalimumab-ryvk) that more than doubles drug substance output per batch. While the disclosure involves regulatory approval, the core event is an operational/manufacturing milestone—process optimization and capacity expansion—rather than a discrete regulatory filing or approval of a new product. The announcement emphasizes manufacturing productivity gains and operational flexibility, making it an operational achievement rather than a financial, governance, or legal event. This is material to investors as it affects the company's ability to meet growing demand and optimize existing infrastructure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T12:00:42.754049+00:00","company_name":"Alvotech","ticker":"ALVOW","filing_date":"2026-10-20"}]}